SCD and ventricular event rates in a Japanese population: Primary results from the Heart Failure Indication and Sudden Cardiac Death Prevention Trial

Clinical course and related costs of patients with type 2 diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people

Potential Implications of Expanded FDA Labeling for Sacubitril/Valsartan in the United States

Prescription Fill Patterns of Guideline-Directed Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States

Higher Alkaline Phosphatase Mean and Variability Predict Heart Failure and All-cause Mortality

Heart Failure Drug Titration, Discontinuation and Mortality and HF Hospitalization Risk: A Multinational Observational Study (US, UK and Sweden)

A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction: insights from the ESC-HFA EORP Heart Failure Long-Term Registry

Eligibility for dapagliflozin and empagliflozin in real-world heart failure based on DAPA-HF, DELIVER, EMPEROR-Reduced and EMPEROR-Preserved selection criteria

The risk of all-cause death after COVID-19 hospital admission among patients with prior heart failure, chronic kidney disease and cardiorenal syndrome: a 12 month follow-up observational study

Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs. reduced ejection fraction based on the 2021 definition and classification of heart failure